Excellent points everyone!
Badaimata, I much appreciate your input and definitely believe the quality of a study is crucial and agree I can't imagine how anyone could sort the kitty from the litter when it comes to the combo of MS + aging so I will keep that in mind as I read this article. My initial thought was due to it being a meta analysis of 38 clinical trials that although some of the studies might be lacking it is unlikely all of them are flawed although as you point out data can be presented in a skewed manner.
I'm slammed the next few days but hope to read it on Friday. I was waiting to access it at work but it is in fact available on line without a subscription.
https://www.frontiersin.org/articles...017.00577/full
Frontiers in Neurology is reported to be a peer reviewed journal.
https://www.frontiersin.org/journals/neurology
The other easily addressed concern includes the author's conflicts of interest and a lead author actually has an interest patents of a MS medication which is a significant litmus test, imo. The funding appears to be above board also:
"Conflict of Interest Statement
BB declares the following COI: she is co-inventor on several patents related to daclizumab therapy for MS and, as such, has received patent royalty payments from the NIH. The remaining authors have no competing interests to declare.
Funding
This study was supported by the Intramural Research Program of the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH)."
Badaimata, I much appreciate your input and definitely believe the quality of a study is crucial and agree I can't imagine how anyone could sort the kitty from the litter when it comes to the combo of MS + aging so I will keep that in mind as I read this article. My initial thought was due to it being a meta analysis of 38 clinical trials that although some of the studies might be lacking it is unlikely all of them are flawed although as you point out data can be presented in a skewed manner.
I'm slammed the next few days but hope to read it on Friday. I was waiting to access it at work but it is in fact available on line without a subscription.
https://www.frontiersin.org/articles...017.00577/full
Frontiers in Neurology is reported to be a peer reviewed journal.
https://www.frontiersin.org/journals/neurology
The other easily addressed concern includes the author's conflicts of interest and a lead author actually has an interest patents of a MS medication which is a significant litmus test, imo. The funding appears to be above board also:
"Conflict of Interest Statement
BB declares the following COI: she is co-inventor on several patents related to daclizumab therapy for MS and, as such, has received patent royalty payments from the NIH. The remaining authors have no competing interests to declare.
Funding
This study was supported by the Intramural Research Program of the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH)."
Comment